A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-56418 Sodium in Subjects With Endometriosis.

Trial Profile

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-56418 Sodium in Subjects With Endometriosis.

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Jan 2013

At a glance

  • Drugs Elagolix (Primary)
  • Indications Dysmenorrhoea; Endometriosis; Pelvic pain
  • Focus Therapeutic Use
  • Acronyms Daisy-PETAL
  • Sponsors Neurocrine Biosciences
  • Most Recent Events

    • 03 Feb 2012 Actual initiation date changed from Sep 2009 to Aug 2009 as reported by ClinicalTrials.gov.
    • 19 Oct 2011 Abbott Laboratories identified as an additional study sponsor and details added
    • 19 Oct 2011 Results presented at the 67th Annual Meeting of the American Society for Reproductive Medicine.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top